Literature DB >> 12457166

Breast cancer: aromatase inhibitors take on tamoxifen.

Mitch Dowsett1, Anthony Howell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12457166     DOI： 10.1038/nm1202-1341

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.

Authors:  Kaitlyn J Andreano; Jennifer G Baker; Sunghee Park; Rachid Safi; Sandeep Artham; Steffi Oesterreich; Rinath Jeselsohn; Myles Brown; Sarah Sammons; Suzanne E Wardell; Ching-Yi Chang; John D Norris; Donald P McDonnell
Journal:  Mol Cancer Ther       Date:  2020-05-07       Impact factor: 6.261

Review 2.  Non-autonomous cell proliferation in the mammary gland and cancer.

Authors:  Robert J Weber; Tejal A Desai; Zev J Gartner
Journal:  Curr Opin Cell Biol       Date:  2017-03-15       Impact factor: 8.382

3.  Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.

Authors:  Elena Lopez-Knowles; Alex Pearson; Gene Schuster; Pascal Gellert; Ricardo Ribas; Belinda Yeo; Ros Cutts; Richard Buus; Isaac Garcia-Murillas; Ben Haynes; Lesley-Ann Martin; Ian Smith; Nick Turner; Mitch Dowsett
Journal:  Br J Cancer       Date:  2018-12-19       Impact factor: 7.640

4.  The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Authors:  Kimberly J Cocce; Jeff S Jasper; Taylor K Desautels; Logan Everett; Suzanne Wardell; Thomas Westerling; Robert Baldi; Tricia M Wright; Kendall Tavares; Alex Yllanes; Yeeun Bae; Jeremy T Blitzer; Craig Logsdon; Daniel P Rakiec; David A Ruddy; Tiancong Jiang; Gloria Broadwater; Terry Hyslop; Allison Hall; Muriel Laine; Linda Phung; Geoffrey L Greene; Lesley-Ann Martin; Sunil Pancholi; Mitch Dowsett; Simone Detre; Jeffrey R Marks; Gregory E Crawford; Myles Brown; John D Norris; Ching-Yi Chang; Donald P McDonnell
Journal:  Cell Rep       Date:  2019-10-22       Impact factor: 9.423

Review 5.  Endocrine therapy resistance: what we know and future directions.

Authors:  David Musheyev; Anya Alayev
Journal:  Explor Target Antitumor Ther       Date:  2022-08-31

6.  An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

Authors:  S Verma; S Sehdev; A Joy; Y Madarnas; J Younus; J A Roy
Journal:  Curr Oncol       Date:  2009-07       Impact factor: 3.677

Review 7.  Status of adjuvant endocrine therapy for breast cancer.

Authors:  Gaia Schiavon; Ian E Smith
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.